DDrare: Database of Drug Development for Rare Diseases

166. 弾性線維性仮性黄色腫
［臨床試験数：11，薬物数：23（DrugBank：6），標的遺伝子数：5，標的パスウェイ数：26］

Searched query = "Pseudoxanthoma elasticum", "PXE"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Aflibercept; CAS No.: 7758-16-9; Disodium Pyrophosphate; Eylea; Intravitreal injection ranibizumab; LANSOPRAZOLE; Lansolprazole; Lansoprazole; Lansoprazole 30mg; Lucentis; Magnesium; Magnesium Oxide; Magnesium oxide; Pyrophosphate; RANIBIZUMAB; RFB002; RFB002, rhuFab V2; RFB002A; Ranibizumab; Ranibizumab injection (0.5 mg); RhuFab V2; SODIUM ACID PYROPHOSPHATE; SODIUM ACID PYROPHOSPHATE SAPP ROR 28 FOOD GRADE

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04441671 (ClinicalTrials.gov)	December 8, 2020	20/1/2020	Oral Pyrophosphate Absorption in PXE Disease	Oral Disodiumpyrophosphate (Na2H2PPi) Absorption in Pseudoxanthoma Elasticum (PXE)	Pseudoxanthoma Elasticum	Drug: Disodium Pyrophosphate	Tampere University Hospital	UMC Utrecht;Hungarian Academy of Sciences	Not yet recruiting	18 Years	80 Years	All	12	Phase 2	NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04441671
(ClinicalTrials.gov)

December 8, 2020

20/1/2020

Oral Pyrophosphate Absorption in PXE Disease

Oral Disodiumpyrophosphate (Na2H2PPi) Absorption in Pseudoxanthoma Elasticum (PXE)

Pseudoxanthoma Elasticum

Drug: Disodium Pyrophosphate

Tampere University Hospital

UMC Utrecht;Hungarian Academy of Sciences

Not yet recruiting

18 Years

80 Years

All

Phase 2

NULL